Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.

J.P.J.E. Sels, J.J.P. Nauta, P.P.C.A. Menheere, B.H.R. Wolfenbuttel, A.C. Nieuwenhuijzen Kruseman

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)

Abstract

Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.

Sels JP, Nauta JJ, Menheere PP, Wolffenbuttel BH, Nieuwenhuijzen Kruseman AC.

Department of Internal Medicine, University Hospital Maastricht, The Netherlands.

In this double-blind, cross-over, placebo-controlled, randomized study, possible extraintestinal effects of miglitol, an absorbable alpha-glucosidase inhibitor, were investigated. Sixteen healthy male volunteers underwent two 75 g oral glucose tolerance tests with concomitant administration of miglitol or placebo. Peak and post-peak areas under the curve values for blood glucose, serum insulin and serum C-peptide after miglitol were not different from those found after placebo. The post-peak AUC-ratio (AUC (peak, 180 min) on miglitol/AUC (peak, 180 min) on placebo) was for glucose 1.15 (CI 0.94-1.40, P = 0.16), for insulin 1.12 (CI 0.95-1.33, P = 0.17) and for C-peptide 0.98 (CI 0.81-1.18, P = 0.82). It is concluded that miglitol exerts no clinically relevant extraintestinal effects on glucose control.

Publication Types:
Clinical Trial
Randomized Controlled Trial
Original languageEnglish
Pages (from-to)503-506
JournalBritish Journal of Clinical Pharmacology
Volume42
DOIs
Publication statusPublished - 1 Jan 1996

Cite this

Sels, J. P. J. E., Nauta, J. J. P., Menheere, P. P. C. A., Wolfenbuttel, B. H. R., & Nieuwenhuijzen Kruseman, A. C. (1996). Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers. British Journal of Clinical Pharmacology, 42, 503-506. https://doi.org/10.1111/j.1365-2125.1996.tb00015.x